Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 2/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30283184 | 1.00 | METAP1 (0.54) | METAP1SLC22A12ATRP2RY1NAMPT | |
| SCHEMBL7848797 | 0.86 | METAP1 (0.52) | METAP1P2RY1NAMPTCYP17A1ALDH1A1 | |
| SCHEMBL28796559 | 0.86 | GAA (0.46) | METAP1SLC22A12ATRP2RY1NAMPT | |
| SCHEMBL38662365 | 0.84 | ATR (0.47) | METAP1SLC22A12ATRNAMPTCYP17A1 | |
| SCHEMBL6868944 | 0.82 | METAP1 (0.56) | METAP1ATRNAMPTCYP17A1TDP2 | |
| SCHEMBL2392457 | 0.82 | METAP1 (0.56) | METAP1ATRNAMPTCYP17A1TDP2 | |
| SCHEMBL15266282 | 0.82 | METAP1 (0.56) | METAP1ATRP2RY1NAMPTCYP17A1 | |
| SCHEMBL30668778 | 0.82 | METAP1 (0.56) | METAP1ATRNAMPTCYP17A1P2RX7 | |
| SCHEMBL8495853 | 0.82 | CETP (0.47) | SLC22A12ATRP2RY1ALDH1A1P2RX7 | |
| SCHEMBL3243855 | 0.82 | METAP1 (0.56) | METAP1ATRNAMPTCYP17A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-6350745-B1 | DIOXO-(PYRIDOOXAZINE) DERIVATIVES; ANTICOAGULANTS; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| US-6239132-B1 | PREVENTING CORONARY ARTERY DISEASE, INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION IN A MAMMAL, | MERCK & CO., INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2000074682-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000064449-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-11-02 | — | — | WO | disclosed |
| US-5700940-A | FOR PRE- OR POSTEMERGENCE SPRAYING OF PLANTS OR SOILS | DOWELANCO (US) | 1997-12-23 | — | — | US | disclosed |
| US-5614469-A | N-pyridinyl[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide herbicides | DOWELANCO (US) | 1997-03-25 | — | — | US | disclosed |
| US-5571775-A | EFFECTIVE ON A BROAD SPECTRUM OF VEGETATION AT LOW APPLICATION RATES | DOWELANCO (US) | 1996-11-05 | — | — | US | disclosed |
| US-5532358-A | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-07-02 | — | — | US | disclosed |
| WO-1996001826-A1 | N-ARYL[1,2,4]TRIAZOLO[1,5-a]PYRIDINE-2-SULFONAMIDE HERBICIDES | DOWELANCO (US) | 1996-01-25 | — | — | WO | disclosed |
| WO-1996001828-A1 | N-PYRIDINYL[1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE-2-SULFONAMIDE HERBICIDES | DOWELANCO (US) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | METAP1 4258/4885SLC22A12 4652/4885ATR 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.